Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301A. A. Miller, Mark J. Ratain, Kouros Owzar et al.|Journal of Clinical Oncology|2007Cited by 16